COVID-19 VACCINATION IN PATIENTS RECEIVING BIOLOGICS FOR THE TREATMENT OF ALLERGIC DISEASES

Abstract

Patients with chronic inflammatory diseases, atopic dermatitis, chronic spontaneous urticaria and asthma do not have an increased risk to get an allergic reaction after coronavirus disease (COVID-19) vaccination. Systemic therapy with monoclonal antibodies such as dupilumab, omalizumab, benralizumab, mepolizumab, which is used to treat severe allergies and type-2 inflammation is effective and safe even in the presence of COVID-19 vaccination. In conclusion, COVID-19 vaccination with the one-week interval between planned biological treatments should be recommended to patients receiving biological therapy.